Anna L.Moscioni

Partner

Cleveland + 1.216.586.7217

Collegati

Condividi

Anna Moscioni represents private fund sponsors in connection with a broad range of issues, including fund structuring and formation, co-investments, regulatory issues and compliance, and internal governance. Her experience spans multiple asset classes, including buyout, venture capital, and private credit. Anna also regularly represents institutional investors in their investments in private funds, including primary investments, secondary investments, co-investments, and single investor funds.

The private funds with which Anna has worked include Cortec Group, Edgewater Capital Partners, Goode Partners, J.F. Lehman, Kirtland Capital Partners, The Riverside Company, Rockwood Equity Partners, and Trinity Hunt Partners.

Esperienze

  • J.F. Lehman raises $1.35 billion for fifth fundJones Day represented J.F. Lehman & Company, LLC in connection with the formation of JFL Equity Investors V, L.P. and its related investment funds.
  • Koch Industries acquired remaining equity stake in InforJones Day advised Koch Equity Development LLC, a subsidiary of Koch Industries, Inc., on the purchase of the remaining equity stake held by Golden Gate Capital in Infor, a global leader in business cloud software specialized by industry.
  • Riverside portfolio company acquires SCRAM Systems®Jones Day represented The Riverside Company in connection with the acquisition and financing by portfolio company LMG Holdings, Inc. of Alcohol Monitoring Systems, Inc. dba SCRAM Systems®, a leading provider of technology-enabled monitoring solutions and groundbreaking offender management software for state and local judicial systems and corrections departments.
  • Riverside Company invests in Clinical Education AllianceJones Day advised The Riverside Company in connection with its investment in and financing of Clinical Education Alliance, LLC (CEA), a provider of interactive live and web-based certified continuing medical education (CME) activities and related training for healthcare professionals.
  • Riverside invests in LMG HoldingsJones Day advised The Riverside Company in connection with its investment in LMG Holdings, Inc., a provider of ignition interlock devices (IIDs) used to help prevent drunk driving.
  • Riverside forms Riverside Capital Appreciation Fund VII, L.P.Jones Day represented The Riverside Company in connection with the formation of Riverside Capital Appreciation Fund VII, L.P. and its parallel fund and alternative investment vehicle.
  • ETS invests $2 million into LearnLaunch-operated, ETS-sponsored accelerator for education start-upsJones Day advised Educational Testing Service in its $2 million investment into a LearnLaunch-operated, ETS-sponsored accelerator for education start-ups.
  • Riverside forms Riverside Credit Solutions Fund I, L.P.Jones Day represented The Riverside Company in connection with the formation of Riverside Credit Solutions Fund I, L.P.
  • Riverside forms Riverside Acceleration Capital Fund II, L.P.Jones Day represented The Riverside Company in connection with the formation of Riverside Acceleration Capital Fund II, L.P.
  • Riverside acquires Naturally Slim®Jones Day represented The Riverside Company in connection with the acquisition and related financing of NS412, LLC (d/b/a Naturally Slim®), a leading digital health platform focused on helping participants reduce Metabolic Syndrome, lose weight, and lead healthier lives.
  • NMP Management Corporation forms Noro-Moseley Partners VIII, L.P.Jones Day advised NMP Management Corporation in the formation of Noro-Moseley Partners VIII, L.P., a venture capital fund ("NMP VIII").
  • Riverside forms Riverside Technology Capital Solutions I, L.P. and its parallel fundJones Day represented The Riverside Company in connection with the formation of Riverside Technology Capital Solutions I, L.P. and its parallel fund.
  • Riverside invests in HemaTerra TechnologiesJones Day represented The Riverside Company in connection with its investment in and related financing of HemaTerra Technologies, a provider of SaaS-based solutions for independent and hospital-based blood collection centers and plasma collection centers.
    •

    September 2024 Commentary

    Investment Advisers Subject to AML and SARs Requirements

    August 2024 Alert

    FinCEN Clarifies Application of Beneficial Ownership Reporting Rules to Dissolved Entities

    March 2024 Alert

    FinCEN Issues Final Rule Extending Beneficial Ownership Information Reporting Deadline for New Entities

    August 2023 Alert

    SEC Adopts Long-Awaited and Heavily Debated Private Fund Adviser Rules

    February 2022 Alert

    SEC's Proposed Rules Target Advisers to Private Funds

    May 2017 Commentary

    SEC's Unwavering Focus on Disclosure of Valuation Methods and Calculation of IRRs by Fund Sponsors

    Prima di procedere all'invio, si prega di notare:

    il contenuto del presente sito web è a scopo esclusivamente informativo e non può essere considerato un parere legale o altro tipo di consulenza professionale. L'invio o la ricezione della presente email non è atta ad instaurare alcun rapporto cliente/avvocato. Le informazioni inviate tramite questa funzione al nostro Studio non saranno coperte da vincolo di riservatezza o confidenzialità fintanto che non ci sia stato conferito e non sia stato da noi accettato un incarico professionale. Inviando il messaggio confermate di aver preso visione e accettato il contenuto di questa informativa.